JP Morgan Chase’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

JP Morgan Chase’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,466	Closed	-$160K	–	7111
2022 Q1	$160K	Buy	7,466 +723	+11%	+$19.1K	﹤0.01%	5299
2021 Q4	$227K	Buy	6,743 +5,584	+482%	+$156K	﹤0.01%	5283
2021 Q3	$30K	Sell	1,159 -1,075	-48%	-$19.2K	﹤0.01%	5971
2021 Q2	$31K	Buy	2,234 +219	+11%	+$2.71K	﹤0.01%	5855
2021 Q1	$21K	Sell	2,015 -62	-3%	-$707	﹤0.01%	5697
2020 Q4	$17K	Sell	2,077 -1,264	-38%	-$9.95K	﹤0.01%	5329
2020 Q3	$25K	Buy	3,341 +888	+36%	+$7.88K	﹤0.01%	5108
2020 Q2	$22K	Buy	2,453 +1,984	+423%	+$20.6K	﹤0.01%	5021
2020 Q1	$4K	Sell	469 -231	-33%	-$2.77K	﹤0.01%	5150
2019 Q4	$10K	Sell	700 -2,500	-78%	-$36.4K	﹤0.01%	5397
2019 Q3	$50K	Buy	+3,200	New	+$44.6K	﹤0.01%	5181

Other funds holding OPNT

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

ACA

Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

JP Morgan Chase's OPNT Position: Q2 2022 in Review

JP Morgan Chase sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q2 2022, closing a stake of 7,466 shares — an estimated $160K sold.

JP Morgan Chase first reported a position in OPNT in Q3 2019 and held it in 11 quarters. The position peaked at $227K in Q4 2021. 33 funds tracked by Wall St. Rank hold OPNT as of Q2 2022.

JP Morgan Chase reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
JP Morgan Chase sold 7,466 Opiant Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $160K.
JP Morgan Chase first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
JP Morgan Chase's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $227K in Q4 2021.
33 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.